3.52
+2.62%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TYK Medicines
Its shares trade on HKEX under the ticker 2410.HK. It has been listed since 20 August 2024. In the fiscal year to 31 December 2025, it reported a net loss of CN¥292.0m. At that date it held total assets of CN¥780.1m and shareholders' equity of CN¥286.8m.
TYK Medicines Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2024-08-20. TYK Medicines Inc is a China-based company mainly engaged in developing and commercializing pharmaceutical products. The firm is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Aug 2024
- Employees
- 144
- Website
- tykmedicines.com ↗
Leadership
Pay as last reported
- Dr. Yusheng WuExecutive Chairman of the Board, Chief Executive Officer, since 2017CN¥2.9m
- Mr. Shaoqing ChenSenior Vice President - Medicinal Chemistry
- Mr. Xiugui ChenSenior Vice President - Clinical and Registration Department
- Mr. Mingyu JiangVice President, Executive Director, Board Secretary, Joint Company Secretary, since 2019
- Ms. Wing Yee WongJoint Company Secretary
- Mr. Zhao DingNon-Executive Director
- Dr. Hong GuNon-Executive Director
- Mr. Chao HeNon-Executive Director
- Dr. Jun LiNon-Executive DirectorCN¥902,000
- Dr. Xiaoying MengNon-Executive Director
- Dr. Yuting LengNon-Executive Independent Director
- Dr. Xiuhua ShenNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is headquartered in Shanghai with 144 employees.
- Focuses on small molecule drug development for pharmaceutical products.
- Has three main products including TY-9591, TY-302, and TY-2136.
Weaknesses
- IPO occurred in 2024, indicating a relatively new public company.
- Limited product portfolio with only three main products.
- Reliance on internal development for key products like TY-2136b.
Opportunities
- Potential growth in biotechnology sector with focus on small molecule drugs.
- Expanding commercialization of pharmaceutical products in China.
- Opportunity to develop additional products in the pipeline.
Threats
- Competition in the biotechnology industry for drug development.
- Regulatory challenges in pharmaceutical commercialization.
- Dependence on internal development for key products may pose risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.